Tenderwize
Wróć do wyszukiwania

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Techniker Krankenkasse·Hamburg, Germany·Deadline Aug 30, 2027 · 370 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-03b - Eculizumab (inkl. der Indikation gMG und NMOSD)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of pharmaceutical product Eculizumab including indications gMG and NMOSD
  • Conclusion of discount contracts under §130a Abs. 8 SGB V
Pokaż pełne podsumowanie

Open-House procedure for discount contracts (Rabattverträge) according to § 130a Abs. 8 SGB V for the active substance Eculizumab including indications generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). The procedure is open to all qualified pharmaceutical entrepreneurs. Contracts have a fixed maximum duration until 31 August 2027, with possible start from 1 April 2026. No estimated value is provided. The tender is not a public procurement under EU directives; it is an Open-House model with no negotiation. Submission is possible at any time until the contract end.

Ryzyka

No guaranteed volume or purchase commitment from the health insurance funds; contracts are discount agreements without...

The tender is explicitly not a public procurement under EU directives; legal recourse lies with social courts, not proc...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG
  • Registered office in Germany, EU, or EEA
  • Valid marketing authorization for the product or entitlement to market

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria applicable.

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House Discount Contracts for Eculizumab (including gMG and NMOSD indications)

Conclusion of drug discount contracts for Eculizumab (including gMG and NMOSD) under an Open-House procedure. All qualified pharmaceutical entrepreneurs can join at any time during the contract period.

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Mar 2026 - Aug 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria applicable.

Termin

Deadline Aug 30, 2027

Szczegóły zamówienia

Data publikacji
24 Feb 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
133422-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3